No categories for this tab

About Us

About PharmaCountry
How It Works
Partnerships
Sustainability
Contact Us

For Buyers

Search Products
Search Services
Find Suppliers
Find Jobs
Find Seekers
Help Center
FAQ
Buyer Protection

For Sellers/Service Providers

Start Selling
Seller Guide
Pricing Plans
Advertising
Seller Support

Top Categories

Active Pharmaceutical Ingredients (APIs)
Finished Dosage Forms
Manufacturing Equipment & Utilities
Excipients & Additives
View All Categories

Stay Connected

[email protected]

24/7 Customer Support

Trusted B2B Platform

SSL Secure Transactions Verified Suppliers Quality Assured B2B Certified Global Network

PharmaCountry

Home

No categories for this tab

About Us

About PharmaCountry
How It Works
Partnerships
Sustainability
Contact Us

For Buyers

Search Products
Search Services
Find Suppliers
Find Jobs
Find Seekers
Help Center
FAQ
Buyer Protection

For Sellers/Service Providers

Start Selling
Seller Guide
Pricing Plans
Advertising
Seller Support

Top Categories

Active Pharmaceutical Ingredients (APIs)
Finished Dosage Forms
Manufacturing Equipment & Utilities
Excipients & Additives
View All Categories

Stay Connected

[email protected]

24/7 Customer Support

Trusted B2B Platform

SSL Secure Transactions Verified Suppliers Quality Assured B2B Certified Global Network

PharmaCountry

Daily News | Pharmacountry Insights

Home/Insights/Daily News

Daily News

Breaking news and updates from the pharmaceutical industry

#Medicus Pharma ×

Daily News Market Analysis Research & Reports Regulatory Updates

Daily News

Sep 18, 2026•3 min read

Pfizer Transfers Discontinued ADC PF-08046031 to Medicus Pharma

Pfizer handed over the CD228‑targeting ADC PF-08046031 to Medicus Pharma, receiving $12 million upfront and potential milestones exceeding $1 billion.